The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | JCAR017 for relapsed/refractory CLL
Tanya Siddiqi, MD, of the City of Hope, Duarte, CA., discusses the results of the TRANSCEND-CLL-004 (NCT03331198) trial investigating the efficacy and safety of the anti-CD19 CAR T-cell product JCAR017 [(lisocabtagene maraleucel (liso-cel)] for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Siddiqi describes the positive response rates witnessed in the trial.
